[A19-84] Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V
Last updated 02.04.2020
Commission awarded on 27.09.2019 by the Federal Joint Committee (G-BA).
First-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR-mutant or ALK-positive NSCLC
Added benefit neither proven in PD-L1 expression (TPS) < 50% nor in PD-L1 expression (TPS) > 50%
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2020-01-02.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.